Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Scion Life Sciences is a venture capital firm based in New York City, established to create and build biotechnology companies that focus on developing clinically transformational or curative medicines. Founded by a team of experienced innovators, company-builders, and investors, Scion aims to improve human health through significant clinical impact. The firm has a strong commitment to advancing healthcare solutions that address pressing medical needs.
Over the past decade, Scion Life Sciences has successfully founded or built ten biotechnology companies, which have collectively advanced more than 15 clinical-stage therapeutics. The firm has generated over $14 billion in public equity value and announced significant M&A proceeds, showcasing its effectiveness in the life sciences sector. Scion operates from its office located at 220 East 42nd Street, 37th / PH Floor, New York, NY 10017.
Scion Life Sciences invests primarily in biotechnology companies that address clinically important problems. Their investment strategy is centered on creating important new medicines rather than focusing on exits. This approach is guided by three key investment pillars: mature modality, well-understood biology and pathophysiology, and standalone viability. The firm actively seeks innovation from both academic and industry partners, as well as developing ideas internally.
Scion's disciplined approach to capital deployment ensures that they invest in projects with the potential for significant clinical impact. They are particularly interested in companies that can demonstrate a clear path to developing therapeutics that meet unmet medical needs. This focus on clinically relevant solutions positions Scion as a valuable partner for startups in the biotechnology sector.
Scion Life Sciences has been instrumental in founding or building ten companies over the last decade. These companies have collectively advanced over 15 clinical-stage therapeutics, contributing to the firm's impressive track record. The portfolio includes companies that have generated more than $14 billion in public equity value and have announced substantial M&A proceeds.
While specific names of the portfolio companies are not disclosed, the firm’s focus on biotechnology and healthcare sectors highlights its commitment to addressing significant clinical challenges. The success of these companies reflects Scion's strategic investment approach and its ability to identify and nurture promising biotechnology ventures.
Samuel Hall, PhD - Managing Partner. Samuel has extensive experience in biotechnology and has led numerous successful investments in the sector.
Aaron Kantoff - Managing Partner. Aaron brings a wealth of knowledge in company-building and investment strategies within life sciences.
Tadd Wessel - Managing Partner. Tadd has a strong background in biotechnology and has been instrumental in developing Scion's investment approach.
William Chour, MD, PhD - Associate. William has expertise in clinical development and contributes to the evaluation of potential investments.
Lalo Flores, PhD - Venture Partner. Lalo's background in research and development enhances Scion's ability to identify promising technologies.
Samuel Hendel, PhD - Associate. Samuel focuses on scientific evaluation and due diligence for potential investments.
Justin Lish - Senior Associate. Justin supports the investment team with market analysis and portfolio management.
Andreas Loew, PhD - Partner. Andreas has a strong track record in biotechnology investments and strategic development.
Huw Nash, PhD - Venture Partner. Huw's experience in drug development adds significant value to Scion's investment strategy.
Romesh Subramanian, PhD - Venture Partner. Romesh brings expertise in clinical research and development to the team.
Elliot Warner, PhD - Associate. Elliot assists in scientific assessments and investment evaluations.
To pitch to Scion Life Sciences, founders should send an email to info@scionlifesciences.com. It is important to include a comprehensive overview of the business, including the therapeutic area, potential impact, and any supporting data. Response times may vary, but founders should expect to hear back within a few weeks.
In recent months, Scion Life Sciences has continued to expand its portfolio, actively founding and building new biotechnology companies. Their focus remains on advancing clinical-stage therapeutics that address significant medical needs.
Scion has also announced substantial M&A proceeds from its portfolio companies, reflecting the successful outcomes of their investments. This activity underscores the firm's commitment to creating impactful healthcare solutions.
What are Scion Life Sciences' investment criteria?
Scion Life Sciences focuses on biotechnology companies that address clinically important problems. They prioritize investments in projects that have the potential to develop clinically transformational or curative medicines.
How can I apply or pitch to Scion Life Sciences?
Founders can pitch their ideas to Scion Life Sciences by sending an email to info@scionlifesciences.com. It is advisable to include a detailed overview of the business model, the therapeutic area of focus, and any preliminary data that supports the potential impact of the proposed solution.
What makes Scion Life Sciences different from other venture capital firms?
Scion Life Sciences emphasizes creating new medicines rather than focusing solely on exits. Their disciplined capital deployment strategy is guided by three investment pillars, which helps them identify and support projects with significant clinical impact.
What is the geographic scope of Scion Life Sciences' investments?
Scion Life Sciences primarily invests in North America, focusing on biotechnology and healthcare sectors within this region.
What is Scion Life Sciences' approach to post-investment involvement?
Scion Life Sciences actively engages with their portfolio companies, providing support and resources to help them navigate the challenges of developing new therapeutics. This includes mentorship, operational support, and guidance on strategic decisions.
What is the typical check size for investments made by Scion Life Sciences?
While specific check sizes are not disclosed, Scion Life Sciences employs a disciplined approach to capital deployment, indicating that they invest significant amounts in projects that align with their investment strategy.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.